NMS Group Competitors and Similar CompaniesClear all
NMS Group's competitors and similar companies include Vivoryon Therapeutics, CytomX Therapeutics, Spectrum Pharmaceuticals and Deciphera Pharmaceuticals.
 NMS Group NMS Group (Nerviano Medical Sciences) is a company focused on the discovery and early development of oncology drugs. |  Vivoryon Therapeutics Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Spectrum Pharmaceuticals Spectrum Pharmaceuticals is a biotechnology company developing drugs to treat oncology and hematology. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. | |
Founding Date | Founding Date N/A | Founding Date 1997 | Founding Date 2008 | Founding Date 2002 | Founding Date 2003 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Nerviano, IT HQ | Locations Halle (Saale), DE HQ München, DE | Locations South San Francisco, US HQ | Locations Henderson, US HQ Irvine, US | Locations Waltham, US HQ Lawrence, US |
Employees | Employees 76 | Employees 14 | Employees 15815% increase | Employees 14638% decrease | Employees 35037% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 69.8 m | Valuation ($) 78 m | Valuation ($) 211.4 m | Valuation ($) 2.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $76.2m (FY, 2025) | Revenue (est.) $10.1m (FY, 2022) | Revenue (est.) $163.4m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $3.7m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit €265k (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $159.6m (FY, 2023) |
Net income | Net income N/A | Net income (€8.9m) (FY, 2025) | Net income ($17.4m) (FY, 2025) | Net income ($75.4m) (FY, 2022) | Net income ($194.9m) (FY, 2023) |
Operating ⚠ | |||||
Patents (Foreign) | Patents (Foreign) N/A | Patents (Foreign) N/A | Patents (Foreign) 4 (FY, 2016) | Patents (Foreign) N/A | Patents (Foreign) 47 (Aug, 2017) |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 13 (FY, 2016) | Patents (US) N/A | Patents (US) 11 (Aug, 2017) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products 3 (FY, 2016) | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 132.4m | Total funding raised $ 3m | Total funding raised $ 714m |
For sources of this data, please see the company profile
View Company Profiles
Vivoryon Therapeutics
HQ
Halle (Saale), DE
Employees
14
Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companySpectrum Pharmaceuticals
HQ
Henderson, US
Employees
146↓ 38% decrease
Spectrum Pharmaceuticals is a biotechnology company developing drugs to treat oncology and hematology.
View companyDeciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View company